APP
PRTK

Avantax Planning Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Avantax Planning Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-169
Closed -$2K – 1279
2018
Q3 		$2K Buy
+169
New +$1.71K ﹤0.01% 1380

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Avantax Planning Partners's PRTK Position: Q4 2018 in Review

Avantax Planning Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 169 shares — an estimated $2K sold.

Avantax Planning Partners first reported a position in PRTK in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Avantax Planning Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 169 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $2K.
  • Avantax Planning Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Paratek Pharmaceuticals, Inc. position peaked at $2K in Q3 2018.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.